Cargando…

Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study

BACKGROUND: In the era of intensity-modulated radiotherapy (IMRT), the role of neoadjuvant chemotherapy (NAC) for locoregionally advanced nasopharyngeal carcinoma (NPC) is under-evaluated. The aim of this study was to compare the efficacy of NAC plus IMRT and concurrent chemoradiotherapy (CCRT) plus...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Wen-Ze, Huang, Pei-Yu, Shi, Jun-Li, Xia, Hai-Qun, Zhao, Chong, Cao, Ka-Jia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4704429/
https://www.ncbi.nlm.nih.gov/pubmed/26739148
http://dx.doi.org/10.1186/s40880-015-0076-9
_version_ 1782408864805683200
author Qiu, Wen-Ze
Huang, Pei-Yu
Shi, Jun-Li
Xia, Hai-Qun
Zhao, Chong
Cao, Ka-Jia
author_facet Qiu, Wen-Ze
Huang, Pei-Yu
Shi, Jun-Li
Xia, Hai-Qun
Zhao, Chong
Cao, Ka-Jia
author_sort Qiu, Wen-Ze
collection PubMed
description BACKGROUND: In the era of intensity-modulated radiotherapy (IMRT), the role of neoadjuvant chemotherapy (NAC) for locoregionally advanced nasopharyngeal carcinoma (NPC) is under-evaluated. The aim of this study was to compare the efficacy of NAC plus IMRT and concurrent chemoradiotherapy (CCRT) plus adjuvant chemotherapy (AC) on locoregionally advanced NPC. METHODS: Between January 2004 and December 2008, 240 cases of locoregionally advanced NPC confirmed by pathologic assessment in Sun Yat-sen University Cancer Center were reviewed. Of the 240 patients, 117 received NAC followed by IMRT, and 123 were treated with CCRT plus AC. The NAC + IMRT group received a regimen that included cisplatin and 5-fluorouracil (5-FU). The CCRT + AC group received cisplatin concurrently with radiotherapy, and subsequently received adjuvant cisplatin and 5-FU. The survival rates were assessed by Kaplan–Meier analysis, and the survival curves were compared using a log-rank test. Multivariate analysis was conducted using the Cox proportional hazard regression model. RESULTS: The 5-year overall survival (OS), locoregional relapse-free survival (LRRFS), distant metastasis-free survival (DMFS), and disease-free survival (DFS) were 78.0, 87.9, 79.0, and 69.8%, respectively, for the NAC + IMRT group and 78.7, 84.8, 76.2, and 65.6%, respectively, for the CCRT + AC group. There were no significant differences in survival between the two groups. In multivariate analysis, age (<50 years vs. ≥50 years) and overall stage (III vs. IV) were found to be independent predictors for OS and DFS; furthermore, the overall stage was a significant prognostic factor for DMFS. Compared with the CCRT + AC protocol, the NAC + IMRT protocol significantly reduced the occurrence rates of grade 3–4 nausea–vomiting (6.5 vs. 1.5%, P = 0.023) and leukopenia (9.7 vs. 0.8%, P = 0.006). CONCLUSIONS: The treatment outcomes of the NAC + IMRT and CCRT + AC groups were similar. Distant metastasis remained the predominant mode of treatment failure.
format Online
Article
Text
id pubmed-4704429
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47044292016-01-20 Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study Qiu, Wen-Ze Huang, Pei-Yu Shi, Jun-Li Xia, Hai-Qun Zhao, Chong Cao, Ka-Jia Chin J Cancer Original Article BACKGROUND: In the era of intensity-modulated radiotherapy (IMRT), the role of neoadjuvant chemotherapy (NAC) for locoregionally advanced nasopharyngeal carcinoma (NPC) is under-evaluated. The aim of this study was to compare the efficacy of NAC plus IMRT and concurrent chemoradiotherapy (CCRT) plus adjuvant chemotherapy (AC) on locoregionally advanced NPC. METHODS: Between January 2004 and December 2008, 240 cases of locoregionally advanced NPC confirmed by pathologic assessment in Sun Yat-sen University Cancer Center were reviewed. Of the 240 patients, 117 received NAC followed by IMRT, and 123 were treated with CCRT plus AC. The NAC + IMRT group received a regimen that included cisplatin and 5-fluorouracil (5-FU). The CCRT + AC group received cisplatin concurrently with radiotherapy, and subsequently received adjuvant cisplatin and 5-FU. The survival rates were assessed by Kaplan–Meier analysis, and the survival curves were compared using a log-rank test. Multivariate analysis was conducted using the Cox proportional hazard regression model. RESULTS: The 5-year overall survival (OS), locoregional relapse-free survival (LRRFS), distant metastasis-free survival (DMFS), and disease-free survival (DFS) were 78.0, 87.9, 79.0, and 69.8%, respectively, for the NAC + IMRT group and 78.7, 84.8, 76.2, and 65.6%, respectively, for the CCRT + AC group. There were no significant differences in survival between the two groups. In multivariate analysis, age (<50 years vs. ≥50 years) and overall stage (III vs. IV) were found to be independent predictors for OS and DFS; furthermore, the overall stage was a significant prognostic factor for DMFS. Compared with the CCRT + AC protocol, the NAC + IMRT protocol significantly reduced the occurrence rates of grade 3–4 nausea–vomiting (6.5 vs. 1.5%, P = 0.023) and leukopenia (9.7 vs. 0.8%, P = 0.006). CONCLUSIONS: The treatment outcomes of the NAC + IMRT and CCRT + AC groups were similar. Distant metastasis remained the predominant mode of treatment failure. BioMed Central 2016-01-06 /pmc/articles/PMC4704429/ /pubmed/26739148 http://dx.doi.org/10.1186/s40880-015-0076-9 Text en © Qiu et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Original Article
Qiu, Wen-Ze
Huang, Pei-Yu
Shi, Jun-Li
Xia, Hai-Qun
Zhao, Chong
Cao, Ka-Jia
Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study
title Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study
title_full Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study
title_fullStr Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study
title_full_unstemmed Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study
title_short Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study
title_sort neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4704429/
https://www.ncbi.nlm.nih.gov/pubmed/26739148
http://dx.doi.org/10.1186/s40880-015-0076-9
work_keys_str_mv AT qiuwenze neoadjuvantchemotherapyplusintensitymodulatedradiotherapyversusconcurrentchemoradiotherapyplusadjuvantchemotherapyforthetreatmentoflocoregionallyadvancednasopharyngealcarcinomaaretrospectivecontrolledstudy
AT huangpeiyu neoadjuvantchemotherapyplusintensitymodulatedradiotherapyversusconcurrentchemoradiotherapyplusadjuvantchemotherapyforthetreatmentoflocoregionallyadvancednasopharyngealcarcinomaaretrospectivecontrolledstudy
AT shijunli neoadjuvantchemotherapyplusintensitymodulatedradiotherapyversusconcurrentchemoradiotherapyplusadjuvantchemotherapyforthetreatmentoflocoregionallyadvancednasopharyngealcarcinomaaretrospectivecontrolledstudy
AT xiahaiqun neoadjuvantchemotherapyplusintensitymodulatedradiotherapyversusconcurrentchemoradiotherapyplusadjuvantchemotherapyforthetreatmentoflocoregionallyadvancednasopharyngealcarcinomaaretrospectivecontrolledstudy
AT zhaochong neoadjuvantchemotherapyplusintensitymodulatedradiotherapyversusconcurrentchemoradiotherapyplusadjuvantchemotherapyforthetreatmentoflocoregionallyadvancednasopharyngealcarcinomaaretrospectivecontrolledstudy
AT caokajia neoadjuvantchemotherapyplusintensitymodulatedradiotherapyversusconcurrentchemoradiotherapyplusadjuvantchemotherapyforthetreatmentoflocoregionallyadvancednasopharyngealcarcinomaaretrospectivecontrolledstudy